16 results
6-K
EX-10.1
IFRX
InflaRx N.V.
21 Dec 22
Current report (foreign)
7:45am
the Regulatory Documents at its own expense and risk and shall hold INFLARX harmless at all times of any liabilities, claims for damages or personal injuries … that and if so to which extent such damages or injuries were due to gross negligence or willful misconduct on the part of INFLARX. Staidson shall use
F-3
IFRX
InflaRx N.V.
8 Jul 20
Shelf registration (foreign)
12:00am
and reperfusion related injuries, acute lung injury and pneumonia.
The issued U.S. and foreign patents are expected to expire in 2030, excluding any additional
424B5
IFRX
InflaRx N.V.
20 Jul 20
Prospectus supplement for primary offering
9:21am
in treating diseases such as ischemia and reperfusion related injuries, acute lung injury and pneumonia.
The issued U.S. and foreign patents
424B5
IFRX
InflaRx N.V.
11 Apr 23
Prospectus supplement for primary offering
4:11pm
on the jurisdiction of the applicable patent, specifically cover the use of such antibodies in treating diseases such as ischemia and reperfusion related injuries
424B5
IFRX
InflaRx N.V.
13 Apr 23
Prospectus supplement for primary offering
8:48am
of the applicable patent, specifically cover the use of such antibodies in treating diseases such as ischemia and reperfusion related injuries, acute lung
424B5
jm5cma3g9
24 Feb 21
Prospectus supplement for primary offering
5:16pm
424B5
6fpy3vz9g45t1b4
26 Feb 21
Prospectus supplement for primary offering
5:10pm
20-F
8o0x7381ih6xco pnw
29 Mar 18
Annual report (foreign)
12:00am
20-F/A
2hbylb 8o
29 Mar 19
Annual report (foreign) (amended)
4:23pm
F-1
9nhdce 6w
2 May 18
Registration statement (foreign)
7:10am
424B4
a4bumn khc3t4y7k
7 May 18
Prospectus supplement with pricing info
4:47pm
- Prev
- 1
- Next